Skip to main content

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in April 2022 Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, and management will be involved in two upcoming conferences. GNPX presenters will include chief financial officer Ryan Confer and chief medical officer Mark Berger. The conference presentations will spotlight the company’s gene therapies for cancer and diabetes. Confer will be presenting at NobleCon 18, which is slated for April 19–21, 2022, in Hollywood, Florida; Confer’s presentation is scheduled to begin at 11:30 a.m. ET on April 20. A high-definition, video webcast of the presentation will be available on the company’s website as well as part of all the conference presentations available at Noble Capital Markets’ Conference website. Berger will be presenting at the virtual Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mediterranean. That event is scheduled for April 20–22, 2022, and Berger’s presentation will be available on demand beginning April 20. According to the company, this event offers in-person and prerecorded virtual presentations by leading public and private companies.

To view the full press release, visit https://ibn.fm/ypfBO

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which the company believes is the first systemic, gene-therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell-signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In 2020, the U.S. Food and Drug Administration granted fast track designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso(R) (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted fast track designation for REQORSA for NSCLC in combination therapy with Merck & Co’s Keytruda(R) (pembrolizumab) for patients whose disease progressed after treatment with Keytruda. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.